T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory ...

O RLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination ...

The global CAR T-Cell Therapy for Multiple Myeloma market is experiencing transformative growth, driven by advances in BCMA-targeted therapies like FDA-approved Abecma and Carvykti. These treatments ...

Carvykti’s emerging Phase III data shows that a single early-line infusion can deliver durable, treatment-free remissions ...

Data were shared at the 67th Annual Meeting of the American Society of Hematology (ASH) ORLANDO, Fla.--(BUSINESS WIRE)--December 8, 2025-- Opna Bio, ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second lineData suggest ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

Bispecific antibodies talquetamab and teclistamab show promising results in treating relapsed/refractory multiple myeloma with extramedullary disease, achieving high response rates. With a median ...

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational ...

Transcription: Colleen Moretti: What is relapsed/refractory multiple myeloma? How does it differ from typical disease? Dr. Saad Usmani: Relapsed and/or refractory myeloma is myeloma that has come back ...